This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Osamu "Sam" Sato, PhD
Executive Director, R&D Planning Department at Daiichi Sankyo Co., Ltd.
Speaker

Profile

Prof. Osamu Sato is currently an Executive Director, R&D Planning Department, R&D Division, Daiichi-Sankyo Co., Ltd. At the position he is in charge of progressive style/type of R&D collaboration with outside organization and so on.

Before the present position, he was a Director, Head of Medical Writing Group, New Drug Regulatory Affairs Department and responsible to prepare NDA dossier and other documents related to R&D in the company.

Outside of the company, he is a Visiting Professor of Kobe University School of Medicine and Kurume University School of Medicine and also as an expert in the field of new technology application for drug discovery and development, especially oligonucleotide drug, personalized medicine and genomics, he is leading Japanese pharmaceutical industry on the fields.

Before he joined Daiichi-Sankyo (former Daiichi) he was a research scientist in the field of cell biology and molecular biology for over 10 years as an associate prof. of Dokkyo University School of Medicine, a research fellow of Tokyo University School of Pharmaceutical Sciences and so on.